Σύγκριση μεθόδων

	Μοντέλο Emax: Φαρμακοδυναμική Ανάλυση Δόσης-Απόκρισης	Φαρμακοκινητική Πληθυσμού
Πεδίο	Φαρμακομετρία	Φαρμακομετρία
Οικογένεια	Regression model	Regression model
Έτος προέλευσης	1981	1977
Δημιουργός	Holford & Sheiner	Sheiner, Rosenberg & Marathe
Τύπος	Nonlinear dose-response regression model	Nonlinear mixed-effects regression model
Θεμελιώδης πηγή	Holford, N. H. G., & Sheiner, L. B. (1981). Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics, 6(6), 429–453.	Sheiner, L. B., Rosenberg, B., & Marathe, V. V. (1977). Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5(5), 445–479.
Εναλλακτικές ονομασίες	Maximum Effect Model, Hyperbolic Emax Model, Sigmoidal Emax Model, Emax Farmakodynamik Modeli	PopPK, Nonlinear Mixed-Effects Modeling, NONMEM Approach, Popülasyon Farmakokinetiği
Συναφείς	2	2
Σύνοψη	The Emax model is a nonlinear pharmacodynamic model that describes the relationship between drug concentration and biological effect. Introduced by Holford and Sheiner in 1981, it characterizes dose-response curves using three fundamental parameters: the maximum achievable effect (Emax), the concentration producing half-maximal effect (EC50), and an optional baseline effect (E0). It remains the standard framework in clinical pharmacology and drug development for quantifying pharmacodynamic dose-response relationships.	Population Pharmacokinetics (PopPK) is a nonlinear mixed-effects modeling framework that characterizes how drugs are absorbed, distributed, metabolized, and eliminated across a patient population, estimating both typical population parameters and the magnitude of between-subject variability. Introduced by Sheiner, Rosenberg, and Marathe in 1977, it enables parameter estimation from sparse, routinely collected clinical data—making it indispensable in drug development, regulatory submissions, and individualized dosing.